Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: Cardiovascular and renal outcomes in a propensity-matched cohort study

Background To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2 diabetes from a population-based cohort.